Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Beamion LUNG-2: uno studio per verificare se Zongertinib (BI 1810631) aiuta le persone affette da cancro polmonare non a piccole cellule avanzato con mutazioni HER2 rispetto al trattamento standard

30 settembre 2026 aggiornato da: Boehringer Ingelheim

Beamion LUNG-2: uno studio multicentrico di fase III, in aperto, randomizzato, con controllo attivo, che valuta la BI 1810631 somministrata per via orale rispetto allo standard di cura come trattamento di prima linea in pazienti con malattia non squamosa non resecabile, localmente avanzata o metastatica. Carcinoma polmonare a piccole cellule che ospita mutazioni del dominio tirosina chinasi HER2

This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including chemotherapy for advanced or metastatic lung cancer. The purpose of this study is to find out whether a medicine called zongertinib (BI 1810631) can slow down the worsening of advanced non-small cell lung cancer better than the standard treatment available. Zongertinib may slow cancer cell growth by inhibiting HER2. This would prolong cancer re-occurrence and increase survival. Current standard treatment is pembrolizumab plus platinum-pemetrexed chemotherapy.

Participants are put into 2 groups by chance. One group receives zongertinib at regular times throughout the study and the other group receives infusions of pembrolizumab, pemetrexed and cisplatin or carboplatin (pembrolizumab plus platinum-pemetrexed chemotherapy) into a vein.

Participants may be in the study up to a maximum of 70 months. During this time, they visit the study site about every 3 weeks for study procedures. Some visits may be conducted remotely later in the study if approved by the study doctor. The doctors regularly check the size of the tumour with a CT or MRI scan, at the beginning of the study and every 6 weeks. After 18 months they check the tumour size every 12 weeks. Doctors regularly check whether the cancer has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects. The time it takes for the cancer to worsen is compared between the 2 groups to see whether the treatment works. The participants also fill in questionnaires about their symptoms and quality of life.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

428

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • CABA, Argentina, 1430
        • Clinica Adventista Belgrano
      • Ciudad Autónoma de Bs As, Argentina, C1426ANZ
        • Instituto Medico Especializado Alexander Fleming
      • Córdoba, Argentina, X5000
        • Instituto Oncologico de Cordoba
      • La Rioja, Argentina, F5300COE
        • Centro Oncologico Riojano Integral (CORI)
      • Rosario, Argentina, S2000DEJ
        • Instituto Medico de la Fundacion Estudios Clinicos
    • New South Wales
      • Randwick, New South Wales, Australia, 2031
        • Prince of Wales Hospital-Randwick-66496
      • St Leonards, New South Wales, Australia, 2065
        • Royal North Shore Hospital-St Leonards-20807
    • Queensland
      • Woolloongabba, Queensland, Australia, 4102
        • Princess Alexandra Hospital
    • Victoria
      • Heidelberg, Victoria, Australia, 3084
        • Austin Health
    • Western Australia
      • Subiaco, Western Australia, Australia, 6008
        • St John of God Subiaco Hospital
      • Krems, Austria, 3500
        • Krems University Hospital
      • Vienna, Austria, 1210
        • Clinic Floridsdorf
      • Anderlecht, Belgio, 1070
        • Brussels - HOSP Jules Bordet
      • Ghent, Belgio, 9000
        • Universitair Ziekenhuis Gent
      • Leuven, Belgio, 3000
        • UZ Leuven
      • Bento Gonçalves, Brasile, 95700-084
        • Associacao Dr. Bartholomeu Tacchini
      • Londrina, Brasile, 86015-520
        • Hospital do Câncer de Londrina
      • Porto Alegre, Brasile, 90610-000
        • Hospital Sao Lucas da PUCRS
      • Rio de Janeiro, Brasile, 22250-905
        • OncoClinicas Rio de Janeiro
      • Santo André, Brasile, 09060-650
        • CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia
      • São José do Rio Preto, Brasile, 15090-000
        • Fundaçao Faculdade Regional de Medicina de Sao Jose do Rio Preto
      • São Paulo, Brasile, 01246-000
        • ICESP - Instituto do Cancer do Estado de Sao Paulo
      • Recoleta, Chile, 8420383
        • Bradford Hill- Centro de Investigacion Clinica
      • Beijing, Cina, 100142
        • Beijing Cancer Hospital
      • Beijing, Cina, 1000021
        • Cancer Hospital of Chinese Academy of Medical Science
      • Chengdu, Cina, 610042
        • West China Hospital, Sichuan University
      • Fuzhou, Cina, 350014
        • Fujian Cancer Hospital
      • Guangzhou, Cina, 510080
        • Guangdong Provincial People's Hospital
      • Hangzhou, Cina, 310022
        • Zhejiang Cancer Hospital
      • Hangzhou, Cina, 310003
        • The First Affiliated Hospital, Zhejiang University
      • Hangzhou, Cina, 310016
        • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
      • Harbin, Cina, 150081
        • Harbin Medical University Cancer Hospital
      • Shanghai, Cina, 200032
        • Fudan University Shanghai Cancer Center
      • Shanghai, Cina, 200032
        • Zhongshan Hospital Affiliated to Fudan University
      • Taizhou, Cina, 317099
        • Taizhou Hospital of Zhejiang Province
      • Wenzhou, Cina, 325000
        • The First Affiliated Hospital of Wenzhou Medical University
      • Wuhan, Cina, 430022
        • Union Hospital Tongji Medical College Huazhong University of Science and Technology
      • Xiamen, Cina, 361003
        • First Affiliated Hospital of Xiamen University
      • Zhengzhou, Cina, 450008
        • Henan Cancer Hospital
      • Cheongiu, Corea del Sud, 28644
        • Chungbuk National University Hospital
      • Goyang, Corea del Sud, 10408
        • National Cancer Center
      • Incheon, Corea del Sud, 21565
        • Gachon University Gil Medical Center
      • Seoul, Corea del Sud, 05505
        • Asan Medical Center
      • Seoul, Corea del Sud, 06351
        • Samsung Medical Center
      • Seoul, Corea del Sud, 03181
        • Kangbuk Samsung Hospital
      • Seoul, Corea del Sud, 03722
        • Severance Hospital
      • Suwon, Corea del Sud, 16247
        • The Catholic University of Korea, St.Vincent's Hospital
      • Bron, Francia, 69677
        • Hopital Louis Pradel
      • Lyon, Francia, 69373
        • CTR Leon Berard
      • Marseille, Francia, 13015
        • HOP Nord
      • Paris, Francia, 75248
        • INS Curie
      • Paris, Francia, 75020
        • HOP Tenon
      • Rennes, Francia, 35000
        • HOP Pontchaillou
      • Strasbourg, Francia, 67091
        • HOP Civil
      • Toulouse, Francia, 31059
        • Hôpital Larrey - CHU de Toulouse
      • Villejuif, Francia, 94805
        • Institut Gustave Roussy
      • Augsburg, Germania, 86156
        • Universitätsklinikum Augsburg
      • Berlin, Germania, 14089
        • Gemeinschaftskrankenhaus Havelhöhe gGmbH
      • Cologne, Germania, 50937
        • Universitätsklinikum Köln (AöR)
      • Dresden, Germania, 01307
        • Universitätsklinikum Carl Gustav Carus Dresden
      • Giessen, Germania, 35392
        • Justus-Liebig Universität Gießen
      • Heidelberg, Germania, 69126
        • Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg
      • Oldenburg, Germania, 26121
        • Pius-Hospital, Oldenburg
      • Tübingen, Germania, 72076
        • Universitätsklinikum Tübingen
      • Aichi, Nagoya, Giappone, 464-8681
        • Aichi Cancer Center Hospital
      • Aomori, Hirosaki, Giappone, 036-8563
        • Hirosaki University Hospital
      • Chiba, Kashiwa, Giappone, 277-8577
        • National Cancer Center Hospital East
      • Ehime, Matsuyama, Giappone, 791-0280
        • Shikoku Cancer Center
      • Fukuoka, Fukuoka, Giappone, 812-8582
        • Kyushu University Hospital
      • Hokkaido, Hakodate, Giappone, 040-8611
        • Hakodate Goryoukaku Hospital
      • Hokkaido, Sapporo, Giappone, 003-0804
        • Hokkaido Cancer Center
      • Ishikawa, Kanazawa, Giappone, 920-8641
        • Kanazawa University Hospital
      • Kanagawa, Kawasaki, Giappone, 216-8511
        • St. Marianna University Hospital
      • Kanagawa, Yokohama, Giappone, 241-8515
        • Kanagawa Cancer Center
      • Kyoto, Kyoto, Giappone, 602-8566
        • University Hospital Kyoto Prefectural University of Medicine
      • Miyagi, Sendai, Giappone, 980-8574
        • Tohoku University Hospital
      • Okayama, Okayama, Giappone, 700-8558
        • Okayama University Hospital
      • Osaka, Osaka, Giappone, 541-8567
        • Osaka International Cancer Institute
      • Shizuoka, Sunto-gun, Giappone, 411-8777
        • Shizuoka Cancer Center
      • Tokyo, Bunkyo-ku, Giappone, 113-8431
        • Juntendo University Hospital
      • Tokyo, Bunkyo-ku, Giappone, 113-8677
        • Komagome Hospital
      • Tokyo, Chuo-ku, Giappone, 104-0045
        • National Cancer Center Hospital
      • Tokyo, Koto-ku, Giappone, 135-8550
        • Japanese Foundation for Cancer Research
      • Wakayama, Wakayama, Giappone, 641-8510
        • Wakayama Medical University Hospital
      • Hong Kong, Hong Kong, 999077
        • Queen Mary Hospital
      • Hong Kong, Hong Kong, 999077
        • Princess Margaret Hospital
      • Hong Kong, Hong Kong, 51727
        • Queen Elizabeth Hospital-Hong Kong-51727
      • Haifa, Israele, 3109601
        • Rambam Medical Center
      • Kfar Saba, Israele, 4428164
        • Meir Medical Center
      • Petah Tikva, Israele, 49100
        • Rabin Medical Center Beilinson
      • Tel Aviv, Israele, 6423906
        • Sourasky Medical Center
      • Bari, Italia, 70124
        • Istituto Tumori Giovanni Paolo II
      • Candiolo (TO), Italia, 10060
        • Istituto Di Candiolo
      • Catania, Italia, 95123
        • Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania
      • Naples, Italia, 80131
        • Istituto Nazionale IRCCS Tumori Fondazione Pascale
      • Parma, Italia, 43100
        • Azienda Ospedaliera Unversitaria di Parma
      • Roma, Italia, 00161
        • AOU Policlinico Umberto I
      • Varese, Italia, 21100
        • A. O. Ospedale Circolo Fond. Macchi
      • Mexico City, Messico, 03100
        • Health Pharma Professional Research S.A. de C.V.
      • México, Messico, 14080
        • Instituto Nacional de Cancerologia
      • México, Messico, 06760
        • Centro Oncologico Personalizado
      • Veracruz, Messico, 91900
        • FAICIC S de RL de C.V.
      • Drammen, Norvegia, N-3004
        • Vestre Viken HF, Drammen Sykehus
      • Oslo, Norvegia, 0379
        • Oslo Universitetssykehus HF, Radiumhospitalet
      • Amsterdam, Olanda, 1066 CX
        • Nederlands Kanker Instituut - Antoni van Leeuwenhoek Amsterdam (METC AVL)
      • Maastricht, Olanda, 6229 HX
        • Maastricht University Medisch Centrum
      • Lodz, Polonia, 93-338
        • Polish Mother's Memorial Hospital - Research Institute
      • Poznan, Polonia, 60-569
        • Greater Poland Center of Pulmonology and Thoracic Surgery
      • Poznan, Polonia, 60693
        • Med Polonia Sp. z o.o
      • Warsaw, Polonia, 02-781
        • Oncology Center-Maria Sklodowska-Curie Institute
      • Rio Piedras, Porto Rico, 00935
        • Pan American Center for Oncology Trials, LLC
      • Lisbon, Portogallo, 1350-352
        • Hospital CUF Tejo
      • Lisbon, Portogallo, 1769-001
        • Centro Hospitalar Lisboa Norte Hospital Pulido Valente
      • Porto, Portogallo, 4100-180
        • Hospital CUF Porto
      • Edinburgh, Regno Unito, EH4 2XU
        • Western General Hospital
      • Leicester, Regno Unito, LE1 5WW
        • Leicester Royal Infirmary
      • London, Regno Unito, SE1 9RT
        • Guy's Hospital
      • London, Regno Unito, SW3 6JJ
        • The Royal Marsden Hospital, Chelsea
      • Sutton, Regno Unito, SM2 5PT
        • The Royal Marsden Hospital, Sutton
      • Singapore, Singapore, 168583
        • National Cancer Centre Singapore
      • Singapore, Singapore, 119228
        • National University Hospital-Singapore-22806
      • A Coruña, Spagna, 15006
        • Complejo Hospitalario Universitario A Coruña
      • Alicante, Spagna, 03010
        • Hospital General Universitario de Alicante
      • Barcelona, Spagna, 08035
        • Hospital Universitari Vall d'Hebron
      • Barcelona, Spagna, 08026
        • Hospital Santa Creu i Sant Pau
      • Barcelona, Spagna, 08908
        • Hospital Duran i Reynals
      • Bilbao, Spagna, 48013
        • Hospital de Basurto
      • Madrid, Spagna, 28041
        • Hospital Universitario 12 de Octubre
      • Madrid, Spagna, 28046
        • Hospital Universitario La Paz
      • Madrid, Spagna, 28009
        • Hospital General Universitario Gregorio Marañón
      • Madrid, Spagna, 28034
        • Hospital Universitario Ramon Y Cajal
      • Málaga, Spagna, 29010
        • Hospital Regional Universitario de Malaga
      • Seville, Spagna, 41013
        • Hospital Virgen del Rocio
      • Valencia, Spagna, 46010
        • Hospital Clinico Universitario de Valencia
    • Alabama
      • Huntsville, Alabama, Stati Uniti, 35805
        • Clearview Cancer Institute
    • Arizona
      • Bullhead City, Arizona, Stati Uniti, 86442
        • Pioneer Research Center - Bullhead City
    • California
      • Beverly Hills, California, Stati Uniti, 90212
        • Precision NextGen Oncology
      • Fresno, California, Stati Uniti, 93710
        • ClinRé 001-022 (Premier Cancer Care and Infusion Center)
      • Glendale, California, Stati Uniti, 91203
        • OPN Healthcare, Inc.
      • La Jolla, California, Stati Uniti, 92037
        • Scripps Green Hospital
      • Los Angeles, California, Stati Uniti, 90067
        • Valkyrie Clinical Trials
      • San Diego, California, Stati Uniti, 92123
        • Sharp Memorial Hospital
    • Missouri
      • Bridgeton, Missouri, Stati Uniti, 63044
        • St. Louis Cancer Care, LLP
      • Springfield, Missouri, Stati Uniti, 65807
        • Oncology Hematology Associates
    • Nevada
      • Reno, Nevada, Stati Uniti, 89511
        • Cancer Care Specialists
    • New York
      • Lake Success, New York, Stati Uniti, 11042
        • Northwell Health
      • The Bronx, New York, Stati Uniti, 10461
        • Montefiore Medical Center
    • North Carolina
      • Wilson, North Carolina, Stati Uniti, 27893
        • Regional Medical Oncology Center
    • Ohio
      • Canton, Ohio, Stati Uniti, 44718
        • Gabrail Cancer Center
    • South Carolina
      • Rock Hill, South Carolina, Stati Uniti, 29732
        • Carolina Blood and Cancer Care Associates, PA
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37203
        • SCRI Oncology Partners
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84112
        • Huntsman Cancer Institute
    • Virginia
      • Fairfax, Virginia, Stati Uniti, 22031
        • Virginia Cancer Specialists, PC
    • Washington
      • Edmonds, Washington, Stati Uniti, 98026
        • Swedish Cancer Institute
      • Issaquah, Washington, Stati Uniti, 98029
        • Swedish Cancer Institute
      • Seattle, Washington, Stati Uniti, 98104
        • Swedish Cancer Institute
      • Gothenburg, Svezia, 413 45
        • Sahlgrenska Universitetsjukhuset
      • Stockholm, Svezia, 171 76
        • Karolinska Universitetssjukhuset Solna
      • Kaohsiung City, Taiwan, 83301
        • Kaohsiung Chang Gung Memorial Hospital
      • Taichung, Taiwan, 404
        • Chung Shan Medical University Hospital
      • Taipei, Taiwan, 100
        • National Taiwan University Hospital
      • Taipei, Taiwan, 106
        • National Taiwan University Cancer Center
      • Taoyuan, Taiwan, 330
        • Chang Gung Memorial Hospital, Linkou

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion criteria:

  1. Signed and dated written informed consent form (ICF) in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
  2. Patients ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signature of the ICF.
  3. Histologically or cytologically confirmed diagnosis of an advanced and/or metastatic non-squamous Non-small cell lung cancer (NSCLC).
  4. Documented Human epidermal growth factor receptor 2 (HER2) mutation in the Tyrosine kinase domain (TKD) as per local lab results.
  5. An archival tumor tissue sample must be submitted to the central laboratory after inclusion of the patient to retrospectively confirm the HER2 status. If no archival tissue is available, this may be acceptable in exceptional cases after written agreement with the sponsor.
  6. Patients who have not received any systemic treatment for unresectable, locally advanced or metastatic disease and are not eligible for curative therapy.
  7. Presence of at least one measurable lesion according to Response evaluation criteria in solid tumors (RECIST) 1.1, as determined by the local site investigator/radiology assessment.
  8. Eligible to receive treatment with the selected platinum-based doublet-chemotherapy (i.e. cisplatin/pemetrexed or carboplatin/pemetrexed) and pembrolizumab in accordance with the Summaries of Product Characteristics (SmPC)/Product Information.

Further inclusion criteria apply.

Exclusion criteria:

  1. Previous or concomitant malignancies other than the one treated in this trial within the last 5 years, except;

    • effectively treated non-melanoma skin cancers
    • effectively treated carcinoma in situ of the cervix
    • effectively treated ductal carcinoma in situ
    • other effectively treated malignancy that is considered cured by local treatment
  2. Tumors with targetable alterations with approved available therapy.

  3. Lung-specific intercurrent clinically significant severe illness based on investigators assessment.

  4. Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.

  5. Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to randomization or planned within 6 months after screening, e.g. hip replacement.

  6. Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patient's ability to comply with the trial or interfere with the evaluation of the safety and efficacy of the test drug.

  7. History or presence of cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of ≥ III or IV, unstable angina or poorly controlled arrhythmia which are considered as clinically relevant by the investigator. Myocardial infarction, stroke, or pulmonary embolism within 6 months prior to randomization.

  8. Any clinically important abnormalities (as assessed by the investigator) in rhythm, conduction, or morphology of resting electrocardiograms, e.g. complete left bundle branch block, third degree heart block.

Further exclusion criteria apply.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Experimental treatment arm

zongertinib only

zongertinib

Altri nomi:
  • BI 1810631, Hernexeos®
Comparatore attivo: Comparator arm

pembrolizumab plus platinum-pemetrexed chemotherapy

pembrolizumab

Altri nomi:
  • Keytruda®

platinum-pemetrexed chemotherapy

platinum-pemetrexed chemotherapy

platinum-pemetrexed chemotherapy

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 determined by blinded central independent review
Lasso di tempo: up to 4 years and 5 months

PFS is defined as the time from randomization until tumor progression according to RECIST 1.1 or death from any cause, whichever occurs earlier.

up to 4 years and 5 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Variazione dal basale alla settimana 25 nel punteggio del dominio della dispnea NSCLC-SAQ
Lasso di tempo: al basale, alla settimana 25
al basale, alla settimana 25
Variazione dal basale alla settimana 25 nel punteggio del dominio della tosse NSCLC-SAQ
Lasso di tempo: al basale, alla settimana 25
al basale, alla settimana 25
Variazione dal basale alla settimana 25 nel punteggio del dominio dell'appetito NSCLC-SAQ
Lasso di tempo: al basale, alla settimana 25
al basale, alla settimana 25
Variazione dal basale alla settimana 25 nel punteggio del dominio della fatica NSCLC-SAQ
Lasso di tempo: al basale, alla settimana 25
al basale, alla settimana 25
Occorrenza di eventi avversi (EA) durante il periodo di trattamento, classificati secondo i Common Terminology Criteria for Adverse Events (CTCAE) versione 5.0
Lasso di tempo: fino a 53 mesi
fino a 53 mesi
Occorrenza di eventi avversi gravi (SAE) durante il periodo di trattamento, classificati secondo la versione 5.0 del CTCAE
Lasso di tempo: fino a 53 mesi
fino a 53 mesi
Key secondary endpoint: Overall Response (OR) according to RECIST 1.1 determined by blinded central independent review
Lasso di tempo: up to 53 months

OR is defined as confirmed best overall response of complete response (CR) or partial response (PR), where best overall response is determined according to RECIST 1.1 from date of randomization until the earliest of disease progression, death, or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow-up or withdrawal of consent.

up to 53 months
Key secondary endpoint: Change from baseline to Week 25 of Non-small cell lung cancer Symptom Assessment Questionnaire (NSCLC-SAQ) total score
Lasso di tempo: at baseline, at week 25

The NSCLC-SAQ is a 7-item patient-reported outcome measure for use in adults to assess symptoms of advanced NSCLC.

It contains five domains and accompanying items that were identified as symptoms of NSCLC: cough (1 item), pain (2), dyspnea (1), fatigue (2), and appetite (1).

The (total) lowest score possible is 0, and the highest (total) score possible is 20. Higher scores indicate more severe symptoms.

at baseline, at week 25
Key secondary endpoint: Overall Survival (OS)
Lasso di tempo: up to 53 months

OS is defined as the time from randomization until death from any cause.

up to 53 months
Duration of response (DoR), determined by blinded central independent review
Lasso di tempo: up to 53 months

DoR is defined as the time from first documented complete response (CR) or partial response (PR) until the earliest of disease progression or death among patients with objective response.

up to 53 months
PFS determined by blinded central independent review
Lasso di tempo: up to 53 months

PFS is defined as the time from randomization until tumor progression or death from any cause, whichever occurs earlier.

up to 53 months
Bi-compartmental PFS, determined by blinded central independent review
Lasso di tempo: up to 53 months

Bi-compartmental PFS is defined as the time from randomization until tumor progression according to RECIST 1.1 or death from any cause, whichever occurs earlier.

up to 53 months
OR determined by blinded central independent review
Lasso di tempo: up to 53 months

OR is defined as confirmed best overall response of CR or PR, from date of randomization until the earliest progression, death, or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow-up or withdrawal of consent.

up to 53 months
Change from baseline to Week 25 in the NSCLC-SAQ pain domain score
Lasso di tempo: at baseline, at week 25

The individual NSCLC-SAQ items use a five-point verbal rating scale from "No <symptom> At All" to "Very severe <symptom>" or from "Never to Always," corresponding to an (item) score of 0 to 4. A higher score indicates more severe symptoms.

at baseline, at week 25
Change from baseline to Week 25 in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) physical functioning domain score
Lasso di tempo: at baseline, at week 25

The EORTC QLQ-C30 is a quality of life questionnaire. It ranges from 0 to 100, higher scores equal worse outcome.

at baseline, at week 25

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Collegamenti utili

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

9 febbraio 2024

Completamento primario (Stimato)

10 dicembre 2026

Completamento dello studio (Stimato)

28 gennaio 2028

Date di iscrizione allo studio

Primo inviato

22 novembre 2023

Primo inviato che soddisfa i criteri di controllo qualità

22 novembre 2023

Primo Inserito (Effettivo)

30 novembre 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

1 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

30 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 1479-0008
  • 2023-504308-27-00 (Identificatore di registro: CTIS)
  • U1111-1294-1407 (Altro identificatore: WHO International Clinical Trials Registry Platform (ICTRP))
  • 2023 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".

Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Periodo di condivisione IPD

One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Criteri di accesso alla condivisione IPD

For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .